IFN-gamma, IL-4 and IL-13 modulate responsiveness of human airway smooth muscle cells to IL-13 by Moynihan, BJ et al.
BioMed CentralRespiratory Research
ssOpen AcceResearch
IFN-γ, IL-4 and IL-13 modulate responsiveness of human airway 
smooth muscle cells to IL-13
Barry J Moynihan1, Barbara Tolloczko1, Souad El Bassam3, Pascale Ferraro2, 
Marie-Claire Michoud1, James G Martin1 and Sophie Laberge*3
Address: 1The Meakins-Christie Laboratories, Department of Medicine, McGill University, Montreal, Canada, 2The Department of Surgery, 
University of Montreal, Montreal, Canada and 3Respiratory Medicine Division, CHU Sainte-Justine, Department of Pediatrics, University of 
Montreal, Montreal, Canada
Email: Barry J Moynihan - barry.moynihan@gmail.com; Barbara Tolloczko - barbara.tolloczko@mcgill.ca; 
Souad El Bassam - elbassams@hotmail.com; Pascale Ferraro - pascale.ferraro@umontreal.ca; Marie-Claire Michoud - marie-
claire.michoud@mcgill.ca; James G Martin - james.martin@mcgill.ca; Sophie Laberge* - sophie.laberge@umontreal.ca
* Corresponding author    
Abstract
Background: IL-13 is a critical mediator of allergic asthma and associated airway
hyperresponsiveness. IL-13 acts through a receptor complex comprised of IL-13Rα1 and IL-4Rα
subunits with subsequent activation of signal transducer and activator of transcription 6 (STAT6).
The IL-13Rα2 receptor may act as a decoy receptor. In human airway smooth muscle (HASM) cells,
IL-13 enhances cellular proliferation, calcium responses to agonists and induces eotaxin
production. We investigated the effects of pre-treatment with IL-4, IL-13 and IFN-γ on the
responses of HASM cells to IL-13.
Methods: Cultured HASM were examined for expression of IL-13 receptor subunits using
polymerase chain reaction, immunofluorescence microscopy and flow cytometry. Effects of
cytokine pre-treatment on IL-13-induced cell responses were assessed by looking at STAT6
phosphorylation using Western blot, eotaxin secretion and calcium responses to histamine.
Results: IL-13Rα1, IL-4Rα and IL-13Rα2 subunits were expressed on HASM cells. IL-13 induced
phosphorylation of STAT6 which reached a maximum by 30 minutes. Pre-treatment with IL-4, IL-
13 and, to a lesser degree, IFN-γ reduced peak STAT6 phosphorylation in response to IL-13. IL-13,
but not IFN-γ, pre-treatment abrogated IL-13-induced eotaxin secretion. Pre-treatment with IL-4
or IL-13 abrogated IL-13-induced augmentation of the calcium transient evoked by histamine.
Cytokine pre-treatment did not affect expression of IL-13Rα1 and IL-4Rα but increased expression
of IL-13Rα2. An anti-IL-13Rα2 neutralizing antibody did not prevent the cytokine pre-treatment
effects on STAT6 phosphorylation. Cytokine pre-treatment increased SOCS-1, but not SOCS-3,
mRNA expression which was not associated with significant increases in protein expression.
Conclusion: Pre-treatment with IL-4 and IL-13, but not IFN-γ, induced desensitization of the
HASM cells to IL-13 as measured by eotaxin secretion and calcium transients to histamine. The
mechanism of IL-4 and IL-13 induced desensitization does not appear to involve either
downregulation of receptor expression or induction of the IL-13Rα2 or the SOCS proteins.
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Asthma and allergy have been associated with a Th2 polar-
ized immunological response to otherwise innocuous
allergens. This Th2 response is associated with increased
levels of the interleukins IL-4 and IL-13 in inflamed tis-
sues [1-3]. The Th2 paradigm has been successfully repro-
duced in animal models of allergen sensitization and
challenge to antigens such as ovalbumin [4-7]. Animal
models demonstrate a role for IL-13 in the development
of airway hyperresponsiveness (AHR); overexpression of
IL-13 in the murine lung induces a phenotype similar to
human asthma, with excess mucus production, goblet cell
hyperplasia, smooth muscle hypertrophy and AHR [8,9].
IL-13 and IL-4/IL-13 knockout mice are protected from
allergen induced AHR [5,10]. Interferon-γ may counteract
the actions of IL-4 and IL-13 in some circumstances. IFN-
γ knockout mice have been shown to have augmented
Th2 responses and IFN-γ knockout mice have enhanced
AHR following allergen challenge that is restored by
administration of recombinant IFN-γ [11].
IL-13 and IL-4 signal through binding to their respective
subunit of a receptor complex comprised of the IL-13
receptor alpha1 (IL-13Rα1) and the IL-4 receptor alpha
(IL-4Rα) with subsequent phosphorylation of Janus acti-
vated kinases (JAKs) and the transcription factor signal
transducer and activator of transcription 6 (STAT6) [12].
These pathways appear to be essential for the develop-
ment of AHR as IL-4Rα and STAT6 deficient mice are pro-
tected from AHR [13-15] and reconstitution of STAT6 in
the epithelium has been shown to be sufficient to restore
IL-13 mediated AHR [16]. IL-13 also binds to the IL-13
receptor alpha2 (IL-13Rα2) with high affinity. The func-
tional significance of this subunit is unclear. It may act as
a decoy receptor to prevent excessive IL-13 signaling as it
has a short intracytoplasmic tail [17-20] but there is also
some evidence that it participates in IL-13 signaling [21].
IL-4 can drive many of the same processes as IL-13
through their shared receptor complex although IL-4 defi-
cient mice are not protected from AHR [22].
Recent evidence indicates that cytokine actions on airway
smooth muscle may be important in the pathobiology of
asthma. The calcium responses to histamine, bradykinin
and methacholine in human airway smooth muscle
(HASM) cells are augmented by IL-13 [23]. The prolifera-
tive response of HASM cells to leukotriene D4 (LTD4) is
also augmented by IL-13 [24]. The expression of the
chemokines eotaxin, eotaxin-3 and TARC is also induced
by IL-13, so IL-13 can be linked to the contractile, prolif-
erative and secretory properties of HASM cells [25-27].
IFN-γ and IL-13 both increase HASM cell stiffness as
assessed by magnetic twisting cytometry and reduce relax-
ation responses induced by isoproterenol [28]. We
hypothesised that the Th2 cytokines IL-4 and IL-13 would
have different effects than the Th1 cytokine IFN-γ on IL-13
signaling in HASM cells. We chose to use STAT6 phospho-
rylation, eotaxin production and calcium responses as
outcomes for IL-13 signaling. ASM is a primary effector of
bronchoconstriction and IL-13 increases the contractility
of HASM cells [23] and promotes STAT6-dependent
eotaxin production [29].
Methods
Cell cultures
Primary cultures of HASM cells were prepared from lung
transplant specimens as previously described [30]. Briefly,
tissue digestion was obtained by incubating the tissues in
HBSS containing collagenase type IV (0.4 mg/ml),
elastase (0.38 mg/ml) and soybean trypsin inhibitor (1
mg/ml) at 37°C for 90 min with gentle shaking. The dis-
sociated cells were collected by filtering through 125 μm
Nytex mesh followed by centrifugation. The pellet was
then reconstituted in growth medium (DMEM-Ham's F12
medium supplemented with 10% fetal bovine serum,
penicillin 10000 unit/ml, streptomycin 10 mg/ml, and
amphotericin 25 μg/ml) and plated in 25-cm2 flask. Con-
fluent cells were detached with a 0.025% trypsin solution
containing 0.02% ethylenediaminetetraacetic acid
(EDTA). Cells were grown on glass cover slips for single
immunofluorescence microscopy and calcium measure-
ments or on 6 well culture dishes for flow cytometric anal-
ysis and for protein and mRNA extraction. Confluent
cultures of HASM cells were serum deprived and supple-
mented with 0.1% bovine serum albumin, 5 μg/ml insu-
lin and 5 μg/ml transferrin 24 h prior to cytokine
treatment. Cells at passages 3–6 were used in all experi-
ments.
Immunofluorescence microscopy
Serum-starved human HASM cells were cultured to semi-
confluence on coverslips, washed with PBS, fixed for 20
min at RT in 4% formaldehyde in PBS and incubated for
1 hour with 10% FBS in PBS before the addition of the pri-
mary antibody. The cells were then incubated for 1 hour
with the following primary antibodies used at the appro-
priate dilution: anti-IL-13Rα1 mAb (CD213a1, Diaclone,
Besançon, France), anti-IL-13Rα2 (CD213a2, Diaclone,
Besançon, France), anti-IL-4Rα (CD124, Pharmingen, BD
Biosciences, Mississauga, Canada). These primary anti-
bodies were detected with Cy2-conjugated goat anti-
mouse IgG (dilution 1/50). Slides were washed twice with
PBS and counterstained with nuclei stain DAPI for 5 min.
As controls, cells were processed either in the absence of
the primary antibody or using an isotype control. After
washing, coverslips were mounted on glass slides, visual-
ized with a Zeiss Axioskop 2 microscope and photographs
were taken using a SPOT camera with SPOT RT software
(SPOT Diagnostic Instruments).Page 2 of 16
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Cells were treated with IL-4, IL-13 or IFN-γ at various con-
centrations for 24 h. Cells were washed with PBS,
detached with a non-enzymatic cell dissociation buffer
and then washed with staining buffer (Dulbecco's PBS,
1% heat-inactivated FBS, 0.09% sodium azide) and centri-
fuged. After blocking Fc receptors, cells were incubated for
3 h on ice with either anti-IL-13Rα1-PE (Diaclone,
Besançon, France), anti-IL-13Rα2-PE (Diaclone,
Besançon, France), or anti-IL-4Rα-FITC (Pharmingen, BD
Biosciences) monoclonal antibodies. Isotype-matched
mouse antibodies were used in all experiments. Cells were
fixed in 2% paraformaldehyde. Flow cytometric acquisi-
tion and analysis of samples were performed on at least
10,000 acquired events on a FACScan (Becton-Dickinson,
Oakville, Canada). Dead cells were excluded by gating out
propidium iodide-positive cells during assessment of
cytokine receptor surface expression. Analysis was per-
formed using Cell Quest software (BD Biosciences).
RNA isolation and real-time RT-PCR
Total RNA was isolated from HASM cells using TRIzol rea-
gent (Invitrogen, Carlsbad, CA), according to the manu-
facturer's instructions. Extracted total RNA was dissolved
in RNA-free water, quantified at 260 nm and 100 ng of
total cellular RNA was used for analysis. One-Step quanti-
tative real-time RT-PCR was conducted using the Quanti-
Tect SYBR Green System (Qiagen, Mississauga, Canada)
on a Mx3000P cycler (Stratagene, La Jolla, CA). The
sequences of the specific primer pairs that were used for
each gene of interest are displayed in Table 1; specific
primers were used at a final concentration of 1 μM. The
reverse transcription was done at 50° for 30 minutes.
Cycling conditions were one cycle at 95°C for 15 min, fol-
lowed by 45 cycles of denaturation at 94° for 15 s, anneal-
ing at 60° for 30 s and extension at 72° for 30 s. Melting
curve analysis was used to document the amplicon specif-
icity. Calibration curves were generated by measuring
serial dilutions of stock cDNA to calculate the amplifica-
tion efficiency. The relative amount of mRNA for each tar-
get gene was normalized to the value obtained for the
housekeeping gene 18S.
Protein extraction and Western Blotting
Confluent cultures of HASM cells were serum starved as
above. After stimulation, cells were washed with ice-cold
PBS and lysed. Samples were sonicated, boiled and pro-
tein content was quantified using Bradford assay. Equal
quantities of protein were loaded per lane. Electrophore-
sis was carried out by using 8% (Phospho-STAT6, STAT6,
rabbit polyclonal IgG, dilution 1:1000, UpState, Lake
Placid, NY, USA; Phospho-ERK, ERK, rabbit polyclonal
IgG, dilution 1:1000, Cell Signaling Technology) or 15%
(rabbit polyclonal anti-SOCS-1 IgG, dilution 1:1000;
mouse monoclonal anti-SOCS-3 IgG, dilution 1:1000,
Abcam Inc, Cambridge, MA) SDS-PAGE gel and proteins
were transferred to nitrocellulose membranes. Mem-
branes were blocked for 1 hour at room temperature for
STAT6 with 5% dried milk in Tris-HCl containing Tween
20 (TTBS) or 1% BSA with EDTA and NaCl in TTBS for
SOCS-1 and SOCS-3. The membranes were incubated
with primary antibodies overnight at 4°C followed by
incubation with secondary antibodies (goat anti-rabbit
IgG HRP conjugated, 1:1500, Upstate, or donkey anti-
mouse IgG HRP conjugated, Jackson Immunology, dilu-
tion 1:10000, as appropriate) at room temperature for 1
hr. Blots were developed by chemiluminescence and the
signals were recorded with Fluoro™ 800 Advanced Fluo-
rescence Imager (Alpha Innotech Corporation, Montreal,
Qc, Canada) and densitometry was performed with Fluor-
ochem™ software. Negative controls without primary anti-
body were performed for all primary antibodies. Blots for
β-actin, STAT6 and ERK were performed in parallel to ver-
ify comparable protein loading.
ELISA
Eotaxin release in supernatants was analysed by means of
ELISA (R&D Systems, Minneapolis, MN) according to the
manufacturer's instructions. Every measurement was per-
formed in duplicate.
Table 1: Primers used for real-time polymerase chain reaction analysis of gene expression.
Gene Forward primer (5' to 3') Reverse primer (5' to 3') Product length (bp)
IL-13Rα1 atctcacccccagaaggtgat cgggactggtattccttc 119
IL-13Rα2 cctttgccgccagtctatctta tcaaaacaccttgctggaatagg 108
IL-4Rα gctatgtcagcatcaccaagattaa cccctgagcatcctggattat 101
SOCS-1 ggaactgctttttcgccctta agcagctcgaagaggcagtc 127
SOCS-3 gtccccccagaagagcctatta ttgacggtcttccgacagagat 118Page 3 of 16
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HASM cells grown on 25 mm diameter coverslips were
used 10–14 days post plating. Cells were incubated for 30
min at 37°C with Hanks' buffer (in mM: NaCl 137,
NaHCO3 4.2, glucose 10, Na2HPO4 3, KCl 5.4, KH2PO4
0.4, CaCl2 1.3, MgCl2 0.5, MgSO40.8, N-2-hydroxyethyl-
piperazine-N'-ethane sulfonic acid [Hepes] 5) containing
5 μM Fura-acetoxymethylester (Fura-2-AM) and 0.02%
pluronic F-127. The loaded cells were then washed and
the coverslips placed in a Leiden chamber (Medical Sys-
tems Corp, Greenville, NY) containing 450 μL of Hanks'
buffer on the stage of an inverted microscope equipped
for cell imaging with a 40× oil objective (Nikon Corp,
Tokyo, Japan). The cells were imaged using an intensified
camera (Videoscope IC 200) and PTI software (Photon
Technology International Inc, Princeton, NJ) at a single
emission wavelength (510 nm) with double excitatory
wavelengths (345 and 380 nm). The fluorescence ratio
(345/380) was measured in individual cells (n = 8 per
slide) and the free [Ca2+]i calculated according to Grynkie-
wicz's formula [31] using a k.d of Ca2+ to Fura-2 of 224
nM Rmax was determined in cells exposed to ionomycin
10-5 M in the presence of 1.3 mM CaCl2 and Rmin in Ca2+
free buffer to which EGTA 10-3 M and ionomycin 10-5 M
had been added. Background fluorescence and autofluo-
rescence were automatically subtracted.
Statistical analysis
Results are expressed as means and standard deviation
values. The statistical analysis was performed using one-
way ANOVA for repeated measurements followed by the
Dunnett test for multiple comparisons. Statistical signifi-
cance was established at a 5% level of confidence.
Results
HASM cells express IL-13 receptor subunits and IL-4, IL-13 
and IFN-γ inhibit STAT6 phosphorylation induced by IL-13
The expression of the IL-13 receptor subunits in HASM
cells was examined using RT-PCR and immunofluores-
cence microscopy. RNA preparation from cultured HASM
cells revealed mRNA expression of the IL-13Rα1 subunit,
the IL-13Rα2 subunit and the IL-4Rα subunit (Figure 1).
We confirmed the expression of all the subunits by
immunofluorescence microscopy (Figure 1). The IL-13
receptor complex was functional as evidenced by STAT6
phosphorylation following stimulation with IL-13 which
reached a maximum by 30 minutes after stimulation. A
dose-response curve of STAT6 phosphorylation showed
that the peak response to IL-13 was observed at a concen-
tration of 15 ng/ml (Figure 2). We chose the submaximal
concentration of 5 ng/ml of IL-13 for all subsequent
experiments investigating the effects of cytokine pre-treat-
ment on IL-13 receptor activation.
To assess the effects of Th2 and Th1 cytokines on IL-13
receptor activation, HASM cells were treated with increas-
ing concentrations of IL-4, IL-13 and IFN-γ for 24 hours
prior to IL-13 stimulation. No wash was performed prior
to IL-13 stimulation in order to better reflect the in vivo
state by a continuous exposure to cytokines in the culture
milieu. Pre-treatment with all three cytokines significantly
reduced peak STAT6 phosphorylation in response to IL-13
which was not associated with reduced total STAT6
expression (Figure 3). The magnitude of the effects of IL-4
and IL-13 pre-treatment on STAT6 phosphorylation
induced by IL-13 was higher than that seen with IFN-γ pre-
treatment. From these experiments, we chose to use the
cytokines at the following concentrations for all subse-
quent experiments: IL-4 and IL-13 (5 ng/ml) and IFN-γ
(10 ng/ml). The effects of cytokine pre-treatment on phos-
phorylation of ERK, another kinase associated with IL-13
receptor activation, was also studied. Cytokine pre-treat-
ment with either IL-4, IL-13 or IFN- γ did not alter IL-13-
induced ERK phosphorylation (data not shown).
IL-4, IL-13 and IFN-γ increase expression of IL-13Rα2 in 
human airway smooth muscle cells
To investigate whether changes in receptor expression
could account for the inhibitory effects of cytokine pre-
treatment on STAT6 phosphorylation induced by IL-13,
HASM cells were treated with IL-4, IL-13 or IFN-γ for var-
ying time periods and mRNA expression of IL-13 receptor
subunits was assessed by real-time RT-PCR. As shown in
Figure 4, IL-13Rα1 and IL-4Rα mRNA expression was
unaffected by cytokine treatment. Both IL-4 and IL-13
increased expression of IL-13Rα2 mRNA by 3 to 4 fold
over control but IFN-γ had no effect. The effects of
cytokine pre-treatment on IL-13 receptor subunits mRNA
expression were associated with changes in surface expres-
sion of receptor subunits using flow cytometry. HASM
cells demonstrated low resting cell surface expression of
all IL-13 subunits. As observed at the mRNA level, IL-4, IL-
13 or IFN-γ did not alter the expression of the IL-13Rα1
(mean fluorescence intensity: non-stimulated: 2.5 ± 0.2;
IL-4-stimulated: 2.45 ± 0.1; IL-13-stimulated: 2.5 ± 0.1;
IFN-γ-stimulated: 2.45 ± 0.1, n = 3) and IL-4Rα subunits
(mean fluorescence intensity: non-stimulated: 3.15 ±
0.75; IL-4-stimulated: 3.0 ± 0.3; IL-13-stimulated: 2.95 ±
0.3; IFN-γ-stimulated: 3.1 ± 0.2, n = 3) indicating that
cytokine pre-treatments did not induce downregulation
of these subunits on the cell surface. However, IL-4 and IL-
13, along with IFN-γ, significantly up-regulated IL-13Rα2
cell surface expression in HASM cells as determined by
both the percentage of positive cells (Figure 5) and the
mean fluorescence intensity (non-stimulated: 7.26 ± 2.52;
IL-4-stimulated: 25.63 ± 10.09; IL-13-stimulated: 24.82 ±
7.96; IFN-γ-stimulated: 22.43 ± 4.42, p < 0.05; Figure 5).
All three cytokines significantly increased IL-13Rα2Page 4 of 16
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Expression of IL-13 receptor subunits in cultured HASMFigure 1
Expression of IL-13 receptor subunits in cultured HASM. The following primary antibodies were used: anti-IL-13Rα1 
mAb, anti-IL-13Rα2 mAb and anti-IL-4Rα mAb. These primary antibodies were detected with Cy2-conjugated goat anti-mouse 
IgG (green). Slides were counterstained with nuclei stain DAPI (blue). As control, cells were processed in the absence of the 
primary antibody and/or the secondary antibody. mRNA transcripts for all subunits in HASM cells obtained from two different 
subjects are also shown: lane 1: IL-13Rα1; lane 2: IL-13Rα2; lane 3: IL-4Rα.
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Concentration-dependent effect of IL-13 on STAT6 phosphorylationFigure 2
Concentration-dependent effect of IL-13 on STAT6 phosphorylation. HASM were stimulated with IL-13 for 30 min-
utes. Levels of phosphorylated STAT6 in cell lysates were detected by Western blot analysis using antibody that recognizes the 
tyrosine-phosphorylated forms of STAT6. A: representative Western blot film. B: Detected phosphorylated STAT6 band den-
sities were measured and densitometric values presented as mean values ± SEM of two independent experiments.
Respiratory Research 2008, 9:84 http://respiratory-research.com/content/9/1/84expression at concentrations as low as 1 ng/ml (data not
shown).
Since the reduction of IL-13-induced STAT6 phosphoryla-
tion following IL-4, IL-13 or IFN-γ pre-treatment was asso-
ciated with increased expression of IL-13Rα2, we
investigated whether blocking the interaction between IL-
13 and this subunit could restore the IL-13-induced
STAT6 response. To this end, HASM cells were pre- treated
with either IL-4, IL-13 or IFN-γ for 24 hours prior to IL-13
stimulation in the presence or absence of a neutralizing
concentration of anti-IL-13Rα2 polyclonal antibody (5
μg/ml) added to cell cultures 1 hour prior to stimulation
with IL-13. The antibody had no effect on IL-13- induced
STAT6 phosphorylation per se. Figure 6 shows that the
inhibitory effect of pre-treatment with either cytokine on
IL-13 induced STAT6 phosphorylation was not altered by
the addition of anti-IL-13Rα2 antibody used at a concen-
tration that blocks 50% of the binding of 100 ng/ml of
rhIL-13 to immobilized rhIL-13Rα2/Fc Chimera (a dose
of IL-13 twenty times in excess of the concentration used
in our study), according to the manufacturer's specifica-
tions. This antibody used at a slightly lower dose (4 μg/
ml) has been shown to be effective in blocking IL-13Rα2-
mediated effects on HASM [32].
IL-4, IL-13 and IFN-γ upregulate SOCS-1 but not SOCS-3 
mRNA expression in HASM cells
SOCS-1 and SOCS-3 are members of the family of sup-
pressors of cytokine signalling (SOCS) proteins involved
in the negative regulation of signalling induced by IL-13
and IL-4. To investigate whether the inhibitory effects of
IL-4, IL-13 and IFN-γ pre-treatment on STAT6 phosphor-
ylation induced by IL-13 may be related to the induction
of such proteins, the effects of IL-4, IL-13 and IFN-γ on the
expression of SOCS-1 and SOCS-3 were determined at the
Effects of IL-4, IL-13 and IFN-γ pre-treatment in STAT6 phosphorylation and total STAT6 protein induced by IL-13Figure 3
Effects of IL-4, IL-13 and IFN-γ pre-treatment in STAT6 phosphorylation and total STAT6 protein induced by 
IL-13. HASM cells were pre-treated with various concentrations of IL-4 (n = 3), IL-13 (n = 3) or IFN-γ (n = 5) for 24 hours and 
then stimulated with IL-13 (5 ng/ml) for 30 minutes. Whole cell lysates were extracted and subjected to Western analysis using 
antibodies that recognize total and phosphorylated forms of STAT6. A: Representative Western blot films. B. Detected phos-
phorylated – STAT6 band densities were measured and the densitometric values were normalized to the IL-13-stimulated 
value. Data are shown as the mean values ± SEM of 3–5 independent experiments. * p < 0.05 compared to IL-13 stimulated 
value in the absence of cytokine pre-treatment.Page 7 of 16
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Time-dependent effects of IL-4, IL-13 and IFN-γ on IL-13Rα1 (A), IL-4Rα (B) and IL-13Rα2 (C) mRNA expressionF gure 4
Time-dependent effects of IL-4, IL-13 and IFN-γ on IL-13Rα1 (A), IL-4Rα (B) and IL-13Rα2 (C) mRNA expres-
sion. HASM were incubated with vehicle, IL-4 (5 ng/ml), IL-13 (5 ng/ml) or IFN-γ (10 ng/ml) for 3, 6, 12 and 24 hours. Receptor 
subtype and 18S mRNA expression was quantified using real-time PCR. Data are expressed as the relative expression in recep-
tor subtype/18S mRNA ratio and compared to unstimulated (vehicle) value of 1 at time 0, for five independent experiments. * 
p < 0.05 compared to cells treated with vehicle (ANOVA).
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Effects of IL-4, IL-13 and IFN-γ on cell surface expression of IL-13α2 receptorFigure 5
Effects of IL-4, IL-13 and IFN-γ on cell surface expression of IL-13α2 receptor. A. Representative flow cytometric 
analysis of IL-13 receptor subunits expression in resting cells. B: Representative flow cytometric analysis of IL-13Rα2 expres-
sion in unstimulated cells and cytokine pre-treated cells. C: HASM cells were incubated with vehicle, IL-4 (5 ng/ml), IL-13 (5 ng/
ml) or IFN-γ (10 ng/ml) for 24 hours. Percentage of positive cells in unstimulated cells and cells treated with IL-4, IL-13 and 
IFN-γ were assessed by flow cytometry and data presented as means ± SEM for 9 independent experiments * p < 0.05 com-
pared to unstimulated cells (ANOVA).
Respiratory Research 2008, 9:84 http://respiratory-research.com/content/9/1/84mRNA and protein levels. IFN-γ and IL-4 significantly
upregulated mRNA expression of SOCS-1 but had no
effect on SOCS-3 mRNA expression (Figure 7). The
increase in the expression of SOCS-1 mRNA following IL-
13 stimulation did not reach statistical significance.
Despite induction of SOCS-1 mRNA, we did not detect a
significant change in protein expression by Western blot
analysis.
Effects of cytokine pre-treatment on IL-13-induced 
eotaxin release
To assess the impact of IL-4, IL-13 and IFN-γ pre-treatment
on a STAT6-dependent physiological outcome [29,33,34],
we measured eotaxin release (Figure 8). Preliminary
experiments revealed that significant but submaximal
eotaxin release was observed when HASM cells were stim-
ulated with IL-13 at a concentration of 5 ng/ml as com-
pared to a higher concentration (5 ng/ml: 1040 ± 135 pg/
Effect of blocking IL-13α2 on cytokine-mediated inhibition of IL-13-induced STAT6 phosphorylationFigure 6
Effect of blocking IL-13α2 on cytokine-mediated inhibition of IL-13-induced STAT6 phosphorylation. HASM 
were pre-treated with IFN-γ (10 or 100 ng/ml), IL-4 (5 ng/ml) or IL-13 (5 ng/ml) 24 hours prior to IL-13 stimulation in the pres-
ence or absence of neutralizing concentration of anti-IL-13α2 polyclonal antibody (5 μg/ml). Phosphorylated STAT6 expression 
was assessed by Western analysis. A and C: Representative Western blots. B and D: Band densities were measured and the 
densitometric values were normalized to the IL-13-stimulated value. Data are shown as the mean values ± SEM of three inde-
pendent experiments. * p < 0.05 (ANOVA).
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Respiratory Research 2008, 9:84 http://respiratory-research.com/content/9/1/84ml; 10 ng/ml:1703 ± 180 pg/ml, p < 0.05). Dose-response
experiments using IL-4 (1–20 ng/ml) indicated that signif-
icant eotaxin release occurred when cell were stimulated
with IL-4 at doses ranging from 1 to 5 ng/ml and that no
further increase in eotaxin release occurred with higher
doses. Therefore, we could not evaluate the effects of IL-4
pre-treatment on IL-13-induced eotaxin production using
our protocol since a maximal eotaxin production was
reached. Pre-treatment with IL-13 resulted in significant
eotaxin release. Subsequent stimulation with IL-13 for 24
hrs did not produce any further increase in eotaxin levels
in cell culture supernatants suggesting that pre-treatment
with IL-13 induced complete functional desensitization of
the IL-13 receptor. Pre-treatment with IFN-γ did not alter
eotaxin production on its own and did not inhibit IL-13-
induced eotaxin production.
Time-dependent effects of IL-4, IL-13 and IFN-γ on SOCS-1 (A) and SOCS-3 (B) mRNA and protein expressionF gure 7
Time-dependent effects of IL-4, IL-13 and IFN-γ on SOCS-1 (A) and SOCS-3 (B) mRNA and protein expres-
sion. HASM were incubated with IL-4 (5 ng/ml), IL-13 (5 ng/ml) or IFN-γ (10 ng/ml) for 3, 6, 12 and 24 hours. SOCS-1, SOCS-
3 and 18S mRNA expression was quantitated using real-time PCR. Data are expressed as the relative expression in SOCS/18S 
mRNA ratio and compared to unstimulated (vehicle) value of 1 at time 0, for 5 independent experiments. * p < 0.05 compared 
to cells treated with vehicle (ANOVA). SOCS-1 (C) and SOCS-3 (D) protein expression was assessed by Western analysis. 
Data are presented as mean ± SEM of densitometric values normalized to β-actin of 3–5 independent experiments.Page 11 of 16
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responses to histamine
We next investigated whether cytokine pre-treatment
modulates the effects of IL-13 on contractile responses of
HASM cells to histamine. IL-13 enhanced the calcium
response to histamine (Figure 9). Our results show that IL-
4 and IL-13 pre-treatment abrogated the enhancement of
calcium response to histamine in the presence of IL-13,
again demonstrating the induction of desensitization to
IL-13. The effects of IFN-γ differed to those of IL-4 and IL-
13. Whereas IFN-γ reduced calcium responses to hista-
mine both in the absence and the presence of IL-13 it did
not abrogate the enhancement of the response to hista-
mine by IL-13.
Discussion
IL-13 has diverse effects on HASM cells that may have
important implications for the pathobiology of asthma.
However the responses of HASM cells to the presence of
IL-13 is likely to be conditioned by the prevalent cytokine
milieu. In this study, we sought to determine how
cytokines representative of both the Th1 and Th2 types
influence the responses of HASM cells to IL-13. The prin-
cipal finding from our study is that the prototypical Th1
cytokine IFN-γ and the Th-2 cytokines IL-4 and IL-13 have
different, although non-opposite, modulatory effects on
IL-13 responses in HASM cells. All three cytokines
induced the IL-13Rα2 subunit of the receptor while leav-
ing the other subunits unaltered. IL-4, IL-13 and IFN-γ
pre-treatment reduced IL-13 induced STAT6 phosphoryla-
tion, although the effect was most pronounced for IL-4
and IL-13. IL-13 pre-treatment abrogated IL-13 induced
eotaxin secretion by HASM cells and also the IL-13-
induced augmentation of the calcium transient evoked by
histamine. Consistent with the lesser effect of IFN-γ pre-
treatment on STAT6 phosphorylation in response to IL-13
there was also no significant reduction in eotaxin release
or IL-13-mediated augmentation of calcium response to
histamine.
The effects of Th1 and Th2 cytokines have been studied on
a number of structural cells of the airways. IFN-γ has been
Effects of cytokine pre-treatment on IL-13-induced eotaxin releaseFigure 8
Effects of cytokine pre-treatment on IL-13-induced eotaxin release. HASM were pre-treated with appropriate vehicle 
(veh), IL-13 (5 ng/ml) or IFN-γ (10 ng/ml) for 24 hours followed by 24 hours stimulation with vehicle or IL-13 (5 ng/ml). Eotaxin 
levels in cell culture supernatants were assessed by ELISA. Data are presented as mean ± SEM of five independent experiments. 
* p < 0.05 compared to cells pre-treated with vehicle and stimulated with vehicle (ANOVA). 








 





	
	

	
Page 12 of 16
(page number not for citation purposes)
Respiratory Research 2008, 9:84 http://respiratory-research.com/content/9/1/84shown to antagonize IL-13-induced STAT6 activity in air-
way epithelial cells, an effect that is time- and dose-
dependent [35]. The inhibitory effect of IFN-γ on IL-4 sig-
nalling has been more extensively studied and has been
demonstrated in both hematopoietic and non-hemat-
opoietic cells including monocytes, lymphocytes, fibrob-
lasts and airway epithelial cells [36-39]. Exposure of
HASM cells to IFN-γ reduced the effects of IL-13 on STAT6
activation but did not appear to have much effect on cal-
cium responses to histamine and on eotaxin secretion,
important measures of contractile and secretory proper-
ties of HASM. Our data also point to a restriction of sig-
nalling through IL-13 in the presence of continuous
amounts of IL-13 or IL-4. The desensitization induced by
IL-4 and IL-13 was substantial and was sufficient to com-
pletely abrogate IL-13-induced effects. This may represent
a negative feedback system by which these Th2 cytokines
prevent persistence of IL-13 signalling at sites of allergic
inflammation. Since these experiments have been per-
formed using airway smooth muscle cells recovered from
non-asthmatic subjects, the results of this investigation
cannot be extrapolated to asthmatic airway smooth mus-
cle cells. Whether these observed effects occur in vivo in
normal or asthmatic airways also remains to be eluci-
dated.
We examined some of the potential mechanisms by which
desensitization of HASM cells to IL-13 may have occurred.
First we addressed the effects of cytokine treatments on IL-
13 receptor subunit expression. The mRNA and cell surface
expression of the IL-13Rα1 and IL-4Rα subunits were unaf-
fected by cytokine treatment suggesting that cytokine pre-
treatment did not induce downregulation of synthesis or
internalization of these subunits. These data are consistent
with findings by Hirst et al. who demonstrated that both IL-
4 and IL-13 do not alter IL-4Rα receptor expression in
HASM cells [34], an effect that differs to that seen in murine
smooth muscle cells [32], and in various immune cells
[40,41]. Based on our findings, we can conclude that the
inhibitory effect of all three cytokines on STAT6 activation
Effects of cytokine pre-treatment on IL-13 augmented calcium response to histamineFigure 9
Effects of cytokine pre-treatment on IL-13 augmented calcium response to histamine. HASM were incubated with 
an appropriate vehicle or IFN-γ (10 ng/ml), IL-4 (5 ng/ml) or IL-13 (5 ng/ml) for 24 hours, followed by 24 hours incubation with 
vehicle (PBS/BSA) or IL-13. Calcium transients were measured in cells stimulated with histamine (1 μM). Data are expressed as 
calcium increase over baseline levels and presented as mean ± SEM of three independent experiments. *p < 0.05 compared to 
values obtained in cells incubated with PBS/BSA.
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Respiratory Research 2008, 9:84 http://respiratory-research.com/content/9/1/84is not mediated by altered cell surface expression of the IL-
13Rα1 and IL-4Rα subunits. However, we observed an
increased surface expression of IL-13Rα2, as evidenced by
both the relative receptor density and the fraction of cells
bearing IL-13Rα2. These data confirm and extend previous
observations showing increased mRNA and cell surface
expression of IL-13Rα2 in human [42] and murine ASM
cells upon IL-13 stimulation. Likewise, lung levels of IL-
13Rα2 mRNA are augmented in transgenic mice overex-
pressing IL-4, IL-13 or IFN-γ [43]. Interestingly, our data
indicate that IFN-γ, unlike IL-4 and IL-13, did not increase
IL-13Rα2 mRNA expression so that the increased cell sur-
face expression of this receptor subset must be mediated by
post-transcriptional or post-translational mechanisms.
Indeed, IFN-γ induces the mobilization of IL-13Rα2 from
intracellular pools to the cell surface in monocytes [20].
Regulation of IL-13Rα2 expression in HASM cells appears
to slightly differ from those obtained in airway epithelial
cells in which reduced IL-13 or IL-4 signalling induced by
pretreatment with either IL-4 or IL-13 is associated with
increase in expression of IL-13Rα2 mRNA and intracellular
protein expression but no increase in cell surface receptor
protein expression [43,44]. Likewise, in airway epithelial
cells, IFN-γ induces IL-13Rα2 mRNA expression that was
not associated with increased cell surface expression [37].
The IL-13Rα2 subunit may serve as either a decoy receptor
in some circumstances [17-20] or as a signalling receptor
in other situations [21]. Transfection of IL-13Rα2 into the
airway epithelial cell line BEAS-2B led to downregulation
of STAT6 phosphorylation [44], suggesting a role for this
subunit in regulating cytokine signalling. Sparse data exist
on the regulatory role of the IL-13Rα2 subunit in IL-13
responses in HASM. Using a blocking anti-IL-13Rα2 anti-
body Kellner et al have shown that this subunit likely
modulates IL-13 responses as indicated by the reversal of
decreases in HASM cell proliferation and acetylcholine-
induced calcium mobilization in presence of high concen-
trations of IL-13 and IL-4 [32]. We used the same blocking
antibody at a slightly higher concentration to assess the
involvement of IL-13Rα2 on cytokine treatment effects on
STAT6 phosphorylation. There was no demonstrable
effect of the blocking antibody on the reduction in STAT6
activation, so that it is unlikely that upregulation of the
expression of IL-13Rα2 accounts for the observation.
These results are at variance with those reported by Kellner
et al and may be related to differences in both the protocol
and the functional outcomes studied. The lower concen-
trations of IL-13 and IL-4 used in our study may be more
physiological than those used in Kellner's study. In other
cell types, IL-13Rα2 inhibits IL-13 signalling in propor-
tion to its level of expression and that these inhibitory
effects could be overcome by high concentrations of IL-13
[45]. We cannot exclude the possibility that IL-13,
although used at a concentration which did not induce
maximal STAT 6 phosphorylation, was still present in suf-
ficient amount in our experimental system to overcome
the effects of the anti-IL-13Rα2 antibody. However in sup-
port of the concept that induction of IL-13Rα2 may not be
the predominant regulator of cytokine signalling in
HASM cells, we found that IFN-γ increased IL-13Rα2
expression slightly more than IL-4 or IL-13 yet was less
effective at reducing IL-13 signalling as assessed by STAT6
phosphorylation.
We then tested whether the inhibition of phosphorylation
of STAT6 was related to the induction of the endogenous
inhibitory proteins, suppressors of cytokine signaling
(SOCS) proteins. SOCS are inducible inhibitors, primarily
in signaling cascades associated with the Jak-STAT path-
way [46]. A variety of studies support this rationale. Over-
expression of SOCS-1 and SOCS-3 in the human embry-
onic kidney HEK293 cells inhibit IL-4 and IL-13 mediated
expression of eotaxin [47]. IFN-γ induces SOCS-1 and
SOCS-3 in airway epithelial cells parallel to the inhibition
of IL-4 signaling [37]. Both IFN-γ and IL-4 induce SOCS-1
gene expression in monocytes and macrophages, an effect
that is associated with reduced activation of STAT6 by IL-
4 [36,48]. IFN-γ-induces SOCS-1 and downregulates
STAT6-dependent eotaxin production in murine fibrob-
lasts [38]. Our data show that IL-4, IL-13 and IFN-γ all
increased SOCS-1, but not SOCS-3, mRNA expression in
HASM cells. The magnitude of induction of SOCS-1
mRNA was, however, substantially less than that reported
for airway epithelial cells [37]. Despite this increase in
SOCS-1 mRNA expression, there was no significant
increase in protein expression. It is therefore unlikely that
induction of SOCS molecules contributed significantly to
the cytokine inhibition of IL-13-induced responses.
Conclusion
In conclusion, IL-13 has effects on eotaxin secretion by
HASM cells and calcium responses of HASM cells to hista-
mine that are abolished by pre-treatment with IL-13. Pre-
treatment with IL-4 also reduced IL-13 receptor signalling
and calcium responses. A reduction in STAT6 phosphor-
ylation in response to IL-13 was also found after treatment
of the cells with IFN-γ but there was no evidence of desen-
sitization of the HASM cells as measured by eotaxin secre-
tion and calcium transients to histamine. The mechanism
of IL-4 and IL-13 induced desensitization is not clear and
does not appear to involve either induction of the IL-
13Rα2 or the SOCS proteins. The observed desensitiza-
tion to IL-13 may be a mechanism for limiting IL-13
induced responses in the airways in the setting of allergic
airway inflammation.
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